Cargando…

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

To evaluate the strategy of using high-dose etoposide mobilization followed by autologous peripheral blood stem cell transplantation (APBSCT) in patients with diffuse large B cell lymphoma (DLBCL) refractory to rituximab-based chemotherapy. Forty patients with refractory DLBCL were treated with high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Yu, Wan, Liping, Yang, Juan, Zhu, Jun, Jiang, Jieling, Li, Su, Song, Xianmin, Wang, Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423309/ https://www.ncbi.nlm.nih.gov/pubmed/30715566 http://dx.doi.org/10.1007/s00277-019-03605-1

Ejemplares similares

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
por: Greenbaum, Adam M., et al.
Publicado: (2018)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients
por: Choi, Jung Yoon, et al.
Publicado: (2020)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
por: Tardy, Magalie P., et al.
Publicado: (2015)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma
por: Mey, Ulrich J.M., et al.
Publicado: (2007)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma
por: Aoyama, Takashi, et al.
Publicado: (2018)

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
por: Seymour, L. K., et al.
Publicado: (1994)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma
por: Ding, Yi, et al.
Publicado: (2023)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Extended use of brentuximab vedotin before autologous stem‐cell transplantation would benefit refractory systemic anaplastic large‐cell lymphoma
por: Koh, Youngil
Publicado: (2018)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas
por: Reimer, Peter
Publicado: (2010)

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma
por: Warry, E.E., et al.
Publicado: (2014)

Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma
por: Shen, Qiu-Dan, et al.
Publicado: (2021)

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
por: Aoki, T, et al.
Publicado: (2015)

Refractory Choriocarcinoma: Complete Response With Oral Etoposide
por: Dhanushkodi, Manikandan, et al.
Publicado: (2016)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

MBCL-03. RESULTS OF HIGH-DOSE THIOTEPA, CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA
por: Gevorgian, Asmik, et al.
Publicado: (2020)

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
por: Wu, Meng, et al.
Publicado: (2018)

Treatment approaches in relapsed or refractory peripheral T-cell lymphomas
por: Foster, Cheryl, et al.
Publicado: (2020)

Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

Evaluating the Efficacy of Modified BeEAM(Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country
por: Ramzi, Mani, et al.
Publicado: (2023)

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis
por: Du, Jun, et al.
Publicado: (2021)

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study
por: Yang, Jun, et al.
Publicado: (2018)

Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China
por: Wang, Yawen, et al.
Publicado: (2022)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma
por: Zhu, Jun, et al.
Publicado: (2019)

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit
por: Mei, Matthew, et al.
Publicado: (2022)

PB2339: CLINICAL OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: THE ROLE OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN AN INTEND TO TREAT POPULATION
por: Mesquita, Isabel Paulos, et al.
Publicado: (2023)

Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review
por: Tian, Linyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_puc6tji1hq64gh4qbsgb4iokj1